Leora Horn Archives
Aug. 13, 2020—Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase 3 study.
TERAVOLT registry tracks outcomes of treatments among people with thoracic cancers sickened by COVID-19
Jun. 12, 2020—New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
Feb. 5, 2020—Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Jun. 6, 2019—Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.
Mar. 14, 2019—Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.
Oct. 25, 2018—Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.
Jun. 13, 2017—Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville – the first was to support her favorite hockey team and the second was to meet a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center.
Mar. 30, 2017—Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.
Oct. 20, 2016—Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.
Nov. 19, 2015—Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has received a 2015 Cancer Clinical Investigator Team Leadership Award (CCITLA) from the National Cancer Institute (NCI).